SGS Acquires CMIC to Bolster North American Bioanalytical Testing
Event summary
- SGS acquired CMIC, INC., a Chicago-based bioanalytical testing provider, on June 3, 2026.
- CMIC's 27,000 sq. ft. GLP-compliant facility supports pre-clinical and clinical drug development.
- This is SGS's second U.S. bioanalytical testing acquisition in as many months.
- CMIC HOLDINGS will continue collaborating with SGS through its Japanese subsidiary.
The big picture
The acquisition strengthens SGS's position in the high-growth bioanalytical testing market, particularly for complex biologics and gene therapies. It reflects broader industry trends of increased outsourcing and regulatory scrutiny in drug development. With over 20 global laboratories, SGS is positioning itself as a one-stop shop for pharmaceutical testing services.
What we're watching
- Market Consolidation
- Whether SGS's aggressive acquisition strategy will trigger competitive responses from other testing firms.
- Regulatory Alignment
- How effectively SGS integrates CMIC's capabilities with its existing network to meet FDA and Health Canada standards.
- Revenue Integration
- The pace at which CMIC's operations contribute to SGS's Strategy 27 goal of doubling North American sales by 2027.
Related topics